Your browser doesn't support javascript.
loading
Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease.
Demirel, Metin; Köktasoglu, Fatmanur; Özkan, Esin; Dulun Agaç, Halime; Gül, Ayse Zehra; Sharifov, Rasul; Sarikaya, Ufuk; Basaranoglu, Metin; Selek, Sahabettin.
Afiliação
  • Demirel M; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey.
  • Köktasoglu F; Health Sciences Institute, Bezmialem Vakif University, Istanbul, Turkey.
  • Özkan E; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey.
  • Dulun Agaç H; Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
  • Gül AZ; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey.
  • Sharifov R; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey.
  • Sarikaya U; Department of Radiology, Department of Gastroenterology, Bezmialem Vakif University, Istanbul, Turkey.
  • Basaranoglu M; Health Sciences Institute, Bezmialem Vakif University, Istanbul, Turkey.
  • Selek S; Department of Medical Services and Techniques, Vocational School of Health Services, Bezmialem Vakif University, Istanbul, Turkey.
Scand J Gastroenterol ; 58(11): 1344-1350, 2023.
Article em En | MEDLINE | ID: mdl-37337892
ABSTRACT

OBJECTIVES:

Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by the accumulation of excessive fat in the liver, which can lead to fibrosis and has an increasing prevalence. NAFLD requires non-invasive diagnostic biomarkers. While typically observed in overweight individuals, it can also occur in non-obese/non-overweight individuals. Comparative studies on non-obese NAFLD patients are scarce. This study aimed to conduct a using liquid chromatography-high resolution mass spectrometry (LC-MS/MS)-based metabolic profiling of non-obese NAFLD patients and healthy controls. MATERIALS AND

METHODS:

The patient group consisted of 27 individuals with NAFLD, while the healthy control group included 39 individuals. Both groups were between 18 and 40 years old, had a BMI of less than 25 and had alcohol consumption less than 20 g/week for men and 10 g/week for women. Serum samples were collected and analyzed using LC-MS/MS. The data were analyzed using the TidyMass and MetaboAnalyst.

RESULTS:

The LC-MS/MS analyses detected significant changes in D-amino acid metabolism, vitamin B6 metabolism, apoptosis, mTOR signaling pathway, lysine degradation, and phenylalanine metabolism pathways in non-obese NAFLD patients. Significant changes were also observed in the metabolites D-pantothenic acid, hypoxanthine, citric acid, citramalic acid, L-phenylalanine, glutamine, and histamine-trifluoromethyl-toluidide, ß-hydroxymyristic acid, DL-Lactic acid, and 3-methyl-2-oxopentanoic. Overall, the study provides valuable insights into the metabolic changes associated with non-obese NAFLD patients and can contribute to the development of non-invasive diagnostic biomarkers for NAFLD.

CONCLUSIONS:

This study sheds light on the metabolic changes in non-obese NAFLD patients. Further research is needed to better understand the metabolic changes associated with NAFLD and to develop effective treatment options.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article